Viral diseases were largely untreatable 40 years ago. The first antivirals were developed in the 1960s, mostly to deal with herpes viruses, and were found using traditional trial-and-error drug discovery methods. This was a time-consuming, hit-or-miss procedure, performed in the absence of a good knowledge of how the virus propagated. It was not until the 1980s, when the full genetic sequences of viruses began to be unraveled, that researchers began to understand the virus life cycle in detail, and exactly what chemicals were needed to inhibit the specific reproductive steps. Now dozens of antiviral treatments are available, and medical research is rapidly exploiting new knowledge and technology to develop additional therapies. However there is still no or limited treatment available for many viral infections. Viral diseases such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) have a major threat on human health in China and throughout the world. Furthermore, established viruses are now developing resistance to available therapies making this another important area for continued drug discovery.
2010, 25(4): 227 doi: 10.1007/s12250-010-3134-0
An estimated 130 million people worldwide are chronically infected with hepatitis C virus (HCV) making it a leading cause of liver disease worldwide. Because the currently available therapy of pegylated interferon-alpha and ribavirin is only effective in a subset of patients, the development of new HCV antivirals is a healthcare imperative. This review discusses the experimental models available for HCV antiviral drug research, recent advances in HCV antiviral drug development, as well as active research being pursued to facilitate development of new HCV-specific therapeutics.
2010, 25(4): 246 doi: 10.1007/s12250-010-3140-2
Over 170 million people worldwide are infected with hepatitis C virus (HCV), a major cause of liver diseases. Current interferon-based therapy is of limited efficacy and has significant side effects and more effective and better tolerated therapies are urgently needed. HCV is a positive, single-stranded RNA virus with a 9.6 kb genome that encodes ten viral proteins. Among them, the NS3 protease and the NS5B polymerase are essential for viral replication and have been the main focus of drug discovery efforts. Aided by structure-based drug design, potent and specific inhibitors of NS3 and NS5B have been identified, some of which are in late stage clinical trials and may significantly improve current HCV treatment. Inhibitors of other viral targets such as NS5A are also being pursued. However, HCV is an RNA virus characterized by high replication and mutation rates and consequently, resistance emerges quickly in patients treated with specific antivirals as monotherapy. A complementary approach is to target host factors such as cyclophilins that are also essential for viral replication and may present a higher genetic barrier to resistance. Combinations of these inhibitors of different mechanism are likely to become the essential components of future HCV therapies in order to maximize antiviral efficacy and prevent the emergence of resistance.
2010, 25(4): 267 doi: 10.1007/s12250-010-3136-y
Ion channels are membrane proteins that are found in a number of viruses and which are of crucial physiological importance in the viral life cycle. They have one common feature in that their action mode involves a change of electrochemical or proton gradient across the bilayer lipid membrane which modulates viral or cellular activity. We will discuss a group of viral channel proteins that belong to the viroproin family, and which participate in a number of viral functions including promoting the release of viral particles from cells. Blocking these channel-forming proteins may be “lethal”, which can be a suitable and potential therapeutic strategy. In this review we discuss seven ion channels of viruses which can lead serious infections in human beings: M2 of influenza A, NB and BM2 of influenza B, CM2 of influenza C, Vpu of HIV-1, p7 of HCV and 2B of picornaviruses.
2010, 25(4): 281 doi: 10.1007/s12250-010-3135-z
2010, 25(4): 294 doi: 10.1007/s12250-010-3138-9
Chronic infection of hepatitis B virus (HBV) presents one of the serious public health challenges worldwide. Current treatment of chronic hepatitis B (CHB) is limited, and is composed of interferon and nucleoside/nucleotide reverse transcriptase inhibitors (NRTI). Interferon is poorly tolerated and is only responsive in a small fraction of CHB patients and NRTIs often face the problem of emergence of drug resistance during long-term treatment. The current treatment of CHB can be improved in several ways including genotyping mutations associated with drug resistance before treatment to guide the choice of NRTIs and suitable combinations among NRTIs and interferon. It is important to continue research in the identification of novel therapeutic targets in the life cycle of HBV or in the host immune system to stimulate the development of new antiviral agents and immunotherapies. Several antiviral agents targeting HBV entry, cccDNA, capsid formation, viral morphogenesis and virion secretion, as well as two therapeutic vaccines are currently being evaluated in preclinical studies or in clinical trials to assess their anti-HBV efficacy.
2010, 25(4): 301 doi: 10.1007/s12250-010-3139-8
哈尔滨兽医研究所王晓钧研究员组发现新的流感病毒复制相关宿主因子并揭示其功能 | J Virol
- [26/04]复旦大学陆路/姜世勃团队揭示抗HIV多肽药物恩夫韦肽（T20）的作用机制新细节 | AIDS
- [24/04]Nature Microbiol | 严景华研究组与高福院士团队合作发现裂谷热病毒治疗性抗体
- [03/04]Cell Rep| 蔡启良团队揭示病毒诱发细胞癌变的关键机制
- [03/04]VS好文推荐 | 出血热相关病毒专题 (2017-2018)
- [29/03]VS好文推荐系列 | 肝炎病毒专题 （2017–2018）
- [25/03]武汉病毒所揭示宿主细胞未折叠蛋白质反应在发热伴血小板减少综合征病毒感染中的重要作用 | J Virol
- [25/03]Nature Comm |程功/田怀玉合作组发现蚊虫在污染水体中孵化可直接感染并传播寨卡病毒